Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration

Synapse. 2008 Nov;62(11):873-6. doi: 10.1002/syn.20573.

Abstract

Binding of (+)-[11C]DTBZ (dihydrotetrabenazine) to the striatal vesicular monoamine transporter (VMAT2) is widely considered to be a stable marker of dopamine neurone integrity. However, we now find that specific binding of a tracer dose of (+)-[11C]DTBZ is modestly increased in rat striatum following dopamine depletion with alpha-methyl-p-tyrosine (alpha-MPT, +14%) or d-amphetamine (d-AMPH, 20 mg/kg, +12%) and decreased following dopamine elevation with gamma-hydroxybutyrate (GHB, -16%) or levodopa (-20%). We suggest that in vivo (+)-[11C]DTBZ binding in imaging studies is subject to competition by vesicular dopamine and, in this respect, is not a "stable" dopamine biomarker as is generally assumed.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Carbon Radioisotopes / metabolism
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Dopamine / metabolism*
  • Dopamine Agents / metabolism
  • Dopamine Agents / pharmacology*
  • Dose-Response Relationship, Drug
  • Male
  • Protein Binding / drug effects
  • Protein Binding / physiology
  • Rats
  • Rats, Sprague-Dawley
  • Synaptic Vesicles / drug effects
  • Synaptic Vesicles / metabolism*
  • Tetrabenazine / analogs & derivatives*
  • Tetrabenazine / metabolism
  • Vesicular Monoamine Transport Proteins / metabolism*

Substances

  • Carbon Radioisotopes
  • Dopamine Agents
  • Slc18a2 protein, rat
  • Vesicular Monoamine Transport Proteins
  • dihydrotetrabenazine
  • Dopamine
  • Tetrabenazine